Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Dec 27, 2022 11:42am

269 Views

Post# 35192454

The Karolinska Institutet develops predictive diagnostic

December 27, 2022 - On the heels of ONCY's AWARE-1 biomarker work involving the development of a predictive diagnostic for the treatment of breast cancer, researchers at Karolinska Institutet in Sweden have developed a method that should be able to predict whether a patient with breast cancer will benefit from a particular treatment or not. The cell-based method has been tested on patients with promising results, according to a study published in PNAS.

From biopsies taken before surgery, the researchers created tumour models for each patient and exposed them to the same drugs the patient received. Thereafter, the drug sensitivity of the models was compared with the patients' treatment response.

The results show that the treatment responses predicted by the tumour model were broadly consistent with the treatment responses the patient subsequently exhibited. For example, the model predicted the treatment response from the chemotherapy drug epirubicin with 90 percent accuracy, while four of four patients treated and tested for anti-HER2 monoclonal antibody drugs showed consistency.

https://www.news-medical.net/news/20221227/Cell-based-method-can-predict-how-breast-cancer-patients-will-respond-to-treatments.aspx

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China